AI assistant
Sending…
Tharimmune, Inc. — Director's Dealing 2022
Jan 11, 2022
34824_dirs_2022-01-11_00b1d16b-6b8f-4ba9-b50f-a9e6c1339e61.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Hillstream BioPharma Inc. (HILS)
CIK: 0001861657
Period of Report: 2022-01-11
Reporting Person: Hess Thomas (Chief Financial Officer)
More from Tharimmune, Inc.
Interim / Quarterly Report
2026
May 13
Annual Report
2026
Mar 31
Regulatory Filings
2026
Mar 31
Regulatory Filings
2026
Mar 3
Regulatory Filings
2026
Mar 3
Regulatory Filings
2026
Feb 18
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11